Literature DB >> 35178167

Novel Isoindolone Compounds as HPK1 Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35178167      PMCID： PMC8842128          DOI： 10.1021/acsmedchemlett.1c00725

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors.

Authors:  Jiamin Zheng; Jun Wu; Xiao Ding; Hong C Shen; Ge Zou
Journal:  Bioorg Med Chem Lett       Date:  2021-02-18       Impact factor: 2.823

Review 2.  Bidirectional feedback between BCR signaling and actin cytoskeletal dynamics.

Authors:  Anshuman Bhanja; Ivan Rey-Suarez; Wenxia Song; Arpita Upadhyaya
Journal:  FEBS J       Date:  2021-06-30       Impact factor: 5.622

Review 3.  Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.

Authors:  Huimin Kong; Enguo Ju; Ke Yi; Weiguo Xu; Yeh-Hsing Lao; Du Cheng; Qi Zhang; Yu Tao; Mingqiang Li; Jianxun Ding
Journal:  Adv Sci (Weinh)       Date:  2021-10-19       Impact factor: 16.806

Review 4.  A perspective on HPK1 as a novel immuno-oncology drug target.

Authors:  Sansana Sawasdikosol; Steven Burakoff
Journal:  Elife       Date:  2020-09-08       Impact factor: 8.140

Review 5.  Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing.

Authors:  Eric Alves; Shahama Taifour; Riccardo Dolcetti; Jonathan Chee; Anna K Nowak; Silvana Gaudieri; Pilar Blancafort
Journal:  Mol Ther Methods Clin Dev       Date:  2021-04-24       Impact factor: 6.698
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.